Clinical Trial: Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)

U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07881952) titled 'Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)' on Oct. 13.

Brief Summary: This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 [Cantharidin and Occlusion in Verruca Epithelium 5]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal application in subjects with common warts.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Common Warts Common Warts (Verruca Vulgaris) Human Papilloma Virus (HPV) Warts

Intervention: COMBINATION_PRODUCT: VP-102

YCANTH (VP-102) is supplied as a topical ...